CDLX Cardlytics, Inc. Insider Trading

CFO Evans David Thomas buys 200,000 shares at blended $0.64 amid 81.7% decline from 52-week high, growing stake 169.6%.

David Thomas, the Chief Financial Officer, executed two separate purchases totaling 200,000 shares for $129,000.00 at a blended average price of $0.64. The current stock price of $0.60 stands -81.7% from the 52-week high of $3.28, and the company is trading at a market cap of $34,563,406.20 against quarterly revenue of $34,319,000.00 and a recent quarterly net loss of $-4,480,000.00. Thomas increased his holdings from 117,930 shares to 317,930 shares, a +169.6% increase in share count. The accumulation occurs as the company faces structural headwinds: annual revenue declined -16.2% year-over-year and the company was unprofitable over its most recent full fiscal year.

Director Hornsey buys 10.0K CDLX shares at $3.59; stock down -82.6% from $202.50 high. Cluster: 2 other insiders bought within 14 days.

Director Liane Hornsey purchased 10,000 shares at $3.59, establishing a new position as the company trades at $35.20, down -82.6% from its 52-week high of $202.50 and down -55.9% over the past 30 days. The company generated $69.6M in quarterly revenue with a net loss of $4.3M and remains unprofitable on a full-year basis. The timing of this purchase coincides with two other insiders buying within the past 14 days, forming a cluster buy pattern during a period of significant stock depreciation. This synchronized activity during a sharp drawdown—combined with current valuation levels that reflect substantial losses from peak prices—warrants examination of whether this represents conviction-driven accumulation at distressed levels or other considerations.

Director Scott Hill buys 40,000 CDLX shares at $3.58 amid -82.6% drop from 52-week high; 3 insiders buy in 14 days

Director Scott Hill purchased 40,000 shares at $3.58 on 2024-08-12, establishing an initial position in Cardlytics. This purchase occurred as the stock trades at $35.20, representing a -82.6% decline from its 52-week high of $202.50, and follows a -62.9% decline over the past 90 days. The company reported revenue of $69.6M in the latest quarter with a net loss of $-4.3M, indicating ongoing unprofitability. Notably, a cluster pattern emerges with 2 other insiders also buying within the past 14 days, marking coordinated insider accumulation during a period of significant price deterioration. The confluence of multiple insider purchases during steep declines and persistent losses warrants scrutiny of whether insiders perceive fundamental value or if additional headwinds may not yet be reflected in the stock price.

Director Klinck buys 14,000 CDLX shares at $3.49; holdings +26.1%; cluster of 3 insider buys in 14 days amid -82.6% decline from 52-week high.

Director John L. Klinck Jr. purchased 14,000 shares of Cardlytics at $3.49 on 2024-08-12, increasing his holdings by 26.1% to 67,593 shares post-transaction. This buy occurs in a cluster context: 2 other insiders also purchased within the past 14 days. The timing is notable given that the stock trades at $35.20, representing -82.6% from its 52-week high of $202.50, and the company reported a net loss of $-4.3M against quarterly revenue of $69.6M. The multi-insider purchase pattern in a sharply depressed environment warrants attention to whether this reflects management's assessment of intrinsic value relative to the 52-week range.